Tumor-Informed Minimal Residual Disease (MRD) Tests Market Report Covering Growth Trends Segments And Forecasts
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
By 2030, How Much Growth In Market Size Is Expected For The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
The market size for urine tumor deoxyribonucleic acid (DNA) testing has observed rapid expansion in recent years. This market is set to increase from $1.18 billion in 2025 to $1.36 billion in 2026, achieving a compound annual growth rate (CAGR) of 14.6%. Historically, this expansion has been driven by factors such as the rising prevalence of urinary cancers, the adoption of PCR-based urine testing, continuous advancements in sequencing technologies, increasing awareness about early cancer detection, and the growth in hospital diagnostic facilities.
The urine tumor deoxyribonucleic acid (DNA) testing market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.36 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.9%. The anticipated expansion during this period stems from factors such as AI-driven urine DNA analysis, the creation of multiplex and high-throughput assays, the broadening scope of personalized medicine, its integration with electronic health records, and an increasing need for non-invasive monitoring solutions. Prominent developments expected in this forecast timeframe encompass non-invasive cancer monitoring, advancements in liquid biopsy, AI-powered genetic analysis, the detection of high-sensitivity urine DNA, and its incorporation into clinical decision support systems.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=98797946&type=smp
What Market Drivers Are Helping Shape The Tumor-Informed Minimal Residual Disease (MRD) Tests Market Expansion?
The market for tumor-informed minimal residual disease (MRD) tests is projected to grow significantly, driven by the increasing occurrence of cancer. Cancer refers to a collection of diseases marked by the uncontrolled proliferation and division of abnormal cells, which can invade surrounding tissues and spread throughout the body. This rising prevalence of cancer is attributable to unhealthy lifestyle factors, including poor diet, insufficient physical activity, smoking, and excessive alcohol consumption, all of which heighten the risk of developing various cancer types. Tumor-informed minimal residual disease (MRD) tests play a crucial role in cancer management by identifying minute amounts of cancer-specific genetic material following treatment, allowing for early detection of relapse and guiding personalized therapeutic decisions. For example, in February 2024, the World Health Organization, a Switzerland-based international organization dedicated to global health policy and public health initiatives, forecasted over 35 million new cancer cases in 2050, marking a 77% increase from the estimated 20 million cases in 2022. Thus, the escalating prevalence of cancer is a key driver for the rapid expansion of the tumor-informed minimal residual disease (MRD) tests market.
How Is Segment Classification Applied In The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
The tumor-informed minimal residual disease (MRD) tests market covered in this report is segmented –
1) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction (PCR)-based, Other Technologies
2) By Product Type: Assay Kits, Instruments, Software, Services
3) By Sample Type: Peripheral Blood (Ctdna), Bone Marrow, Tissue Biopsy, Other Body Fluids
4) By Application: Colorectal Cancer, Lung Cancer, Breast Cancer, Hematological Malignancies, Other Applications
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Next-Generation Sequencing: Targeted Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Single Cell Sequencing, Other Sequencing Approaches
2) By Polymerase Chain Reaction (PCR)-Based: Digital Polymerase Chain Reaction, Real Time Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Other Polymerase Chain Reaction Methods
3) By Other Technologies: Hybrid Capture Based, Bead Based Assays, Electrochemical Detection, Other Emerging Technologies
What Trends Are Impacting The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
Major companies operating in the tumor informed minimal residual disease (MRD) tests market are concentrating on creating advanced solutions, including tissue informed whole genome sequencing (WGS) MRD assays, to identify extremely low quantities of circulating tumor DNA for prompt detection of cancer recurrence and assessment of treatment efficacy. Specifically, a tissue-informed whole genome sequencing (WGS) MRD assay utilizes a patient’s tumor tissue to pinpoint distinct genetic mutations, subsequently tracking these mutations in the blood to identify minimal residual disease even at minute concentrations. For example, in September 2025, Foundation Medicine, Inc., a US-based precision medicine firm, introduced the Tissue-informed WGS MRD test through the FlexOMx Lab. This novel, tumor-informed whole-genome sequencing test, intended for molecular residual disease research, is applicable to cancers from early to late stages. It precisely tracks hundreds to thousands of tumor-specific variants within circulating tumor DNA, enabling the accurate detection of minimal residual disease even at extremely low tumor burdens, and simultaneously offers extensive genomic profiling to improve insights into recurrence and treatment resistance within clinical investigations.
Which Companies Form The Competitive Landscape Of The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
Major companies operating in the tumor-informed minimal residual disease (MRD) tests market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Integrated DNA Technologies Inc., Natera Inc., NeoGenomics Laboratories Inc., Veracyte Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Genetron Holdings Limited, Burning Rock Biotech Co Ltd., Personalis Inc., Foresight Diagnostics Inc., Predicine Inc., Guardant Health Inc.
Access The Complete Tumor-Informed Minimal Residual Disease (MRD) Tests Market Report:
Which Region Commands The Largest Share Of The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
North America was the largest region in the tumor-informed minimal residual disease (MRD) tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor-informed minimal residual disease (MRD) tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Tumor-Informed Minimal Residual Disease (MRD) Tests Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample_request?id=98797946&type=smp
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
